Your browser doesn't support javascript.
loading
The impact of co-surgeons on complication rates and healthcare cost in patients undergoing microsurgical breast reconstruction: analysis of 8680 patients.
Asaad, Malke; Xu, Ying; Chu, Carrie K; Shih, Ya-Chen Tina; Mericli, Alexander F.
Afiliación
  • Asaad M; Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1488, Houston, TX, 77030, USA.
  • Xu Y; Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Chu CK; Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1488, Houston, TX, 77030, USA.
  • Shih YT; Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Mericli AF; Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1488, Houston, TX, 77030, USA. AFMericli@mdanderson.org.
Breast Cancer Res Treat ; 184(2): 345-356, 2020 Nov.
Article en En | MEDLINE | ID: mdl-32803638
ABSTRACT

PURPOSE:

The use of two operating microsurgeons has been shown to improve the efficiency and reduce the operative duration of microsurgical breast reconstruction (MSBR). However, the impact of this practice on healthcare cost has not been previously assessed. The goal of this study is to query a national claims database to assess complication rates and overall cost in patients undergoing MSBR using co-surgeon (CS) vs. single-surgeon (SS) approach.

METHODS:

The study cohort, extracted from the MarketScan database, included all female patients who underwent MSBR between 2010 and 2017. Our primary outcome measure was the difference in total healthcare cost between the two operative groups while differences in complication rates were secondary outcome measures.

RESULTS:

We identified a total of 8680 patients, out of whom 7531 (87%) underwent MSBR with a SS and 1149 (13%) had a CS. Over the study period, the annual incidence rate of MSBR cases using CS increased from 7.2% in 2010 to 23.3% in 2017 (p < 0.001). Following propensity score matching, complications, emergency room visits, readmissions, and reoperations were all similar between the CS and SS groups. The median total healthcare cost was higher for the CS group [US $76,227 (IQR $67,879) vs. $61,340 (IQR $54,318); p < 0.0001],

CONCLUSIONS:

Use of the CS approach in MSBR has become increasingly prevalent over time. Analyses of a national claims database suggested that the use of CS is a safe option for patients undergoing MSBR. Further research is needed to optimize CS utilization from a costs and outcomes perspective.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Mamoplastia / Cirujanos Tipo de estudio: Etiology_studies / Health_economic_evaluation / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Breast Cancer Res Treat Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Mamoplastia / Cirujanos Tipo de estudio: Etiology_studies / Health_economic_evaluation / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Breast Cancer Res Treat Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos